key: cord-1005802-grjm79zd
authors: Tumminia, Andrea; Romano, Raffaella; Brugaletta, Giuseppe; Scicali, Roberto; Biondi, Giuseppina; Oliveri, Rosario; Romano, Marcello; San Lio, Paola Magnano
title: The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: an observational study
date: 2022-04-10
journal: Nutr Metab Cardiovasc Dis
DOI: 10.1016/j.numecd.2022.04.005
sha: f3e2aaed275ff63fd0197ffdbedf794ecf07640b
doc_id: 1005802
cord_uid: grjm79zd

Background and Aims Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase was early identified as a promising therapeutic candidate against COVID-19. Our aim was to evaluate the impact of several metabolic parameters on Remdesivir effectiveness among hospitalized COVID-19 patients. Methods and Results We conducted an observational study on patients with SARS-CoV-2-related pneumonia admitted between May 2020 and September 2021 to the COVID-19 Units of Internal Medicine, Pneumology and Intensive Care of Garibaldi Hospital, Catania, Italy, and treated with Remdesivir. The “Ordinal Scale For Clinical Improvement” was used to assess patients’ clinical improvement within 28 days of hospitalization. Short-term mortality rate was also evaluated. A total of 142 patients with SARS-CoV-2-related pneumonia were studied. The prevalence of obesity (20.7% vs. 41.9%, p=0.03), the average BMI (27.1 ± 4.4 vs. 31.1 ± 6.1, p<0.01) and the mean LDL-C levels (78 ± 19 mg/dl vs. 103 ± 18 mg/dl, p=0.03) were significantly lower in early-improved (EI) compared to not-improved (NI) individuals. Obesity was negatively associated to clinical improvement after Remdesivir (OR 0.48, 95%CI 0.17-0.97, p=0.04). Both obesity (OR 2.82, 95% CI 1.05-7.71, p=0.04) and dyslipidemia (OR 2.78, 95%CI 1.17-7.16, p=0.03) were significantly related to patients’ mortality. Dyslipidemic subjects experienced a slower clinical improvement than non-dyslipidemic ones (Long-Rank p=0.04). Conclusion Our study showed that unfavorable metabolic conditions such as obesity and dyslipidemia could predict a worse clinical response to Remdesivir as well as the mortality in hospitalized COVID-19 patients. Further prospective and larger-scale studies are needed to confirm these preliminary findings.

Since Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) disease (COVID-19) 2 emerged at the end of 2019 in China, it rapidly became a global pandemic [1] . Clinical 3 manifestations of COVID-19 usually range from asymptomatic state or mild infection to severe 4 forms of the disease that are life threatening [2] . This ongoing outbreak has pushed the researchers' 5 efforts to identify which clinical characteristics would have conferred to people an higher risk of 6 getting infected, of developing critical illness and, ultimately, of dying from this disease [3] . On this 7 regard, advanced age, male sex, the presence of chronic illness and/or multiple comorbidities (e.g. 8 chronic lung diseases, cardiovascular diseases, obesity and diabetes mellitus) have been clearly 9 identified as major risk factors for the development of severe COVID-19 [4] [5] [6] [7] . Recent reports also 10 indicated a role of dyslipidemia in severity and mortality from SARS-CoV-2 infection [8, 9] . Afterward, on August 28 th , 2020, authorization of Remdesivir administration was expanded to non-18 severe COVID-19 patients. Finally, on October 22 nd , 2020, Remdesivir became the first drug with 19 admission), malignancies and chronic obstructive pulmonary diseases (COPD). Patients' smoking 1 habit and concomitant medications were also recorded. 2

The previously validated "Ordinal Scale For Clinical Improvement" (OSCI) [12] was used to assess 3 patients' early clinical improvement after Remdesivir (primary outcome), which was defined as the 4 achievement of categories 1-3 on the scale and/or a 2-point reduction of the score (regardless of the 5 starting level) within 28 days of hospitalization. The categories were as follows: 1, not hospitalized 6 and no limitations of activities; 2, not hospitalized, with limitation of activities, home oxygen 7 requirement, or both; 3, hospitalized, not requiring supplemental oxygen and no longer requiring 8 ongoing medical care (used if hospitalization was extended for infection-control or other 9 nonmedical reasons); 4, hospitalized, not requiring supplemental oxygen but requiring ongoing 10 medical care (related to COVID-19 or to other medical conditions); 5, hospitalized, requiring any 11 supplemental oxygen; 6, hospitalized, requiring noninvasive ventilation or use of high-flow oxygen 12 devices; 7, hospitalized, receiving invasive mechanical ventilation or ECMO; and 8, death. 13

Patients were then defined as either early improved (EI) or not-improved (NI) on the basis of 14 clinical achievements of the aforementioned criteria. 15

Secondary outcomes were the time to recovery, defined as the first day, during the 28 days after the 16 first dose of Remdesivir, on which the patient met the above-mentioned criteria, and the short-term 17 (within one month since hospital admission) mortality rate. 18

The study was conducted in compliance with the principles of the Declaration of Helsinki and its 19 later amendments [18] and was approved by the local ethics committee. 20

We estimated that a sample size of 140 patients would have given at least 85% power to detect a 23 difference of 30% in reaching the primary outcome (early clinical improvement after Remdesivir), 24

with an alpha of 0.05. The effect size estimation was based on the rate ratio for recovery (1.29) of 25 the main randomized controlled trial on Remdesivir efficacy, the Adaptive COVID-19 Treatment 1

Shapiro-Wilk and Kolmogorov-Smirnov tests were used to explore the distribution of continuous 3

variables. Graphic analyses of histogram, Q-Q normality graph and asymmetry/standard error or 4 kurtosis/standard error ratio supported the distribution of continuous variables exploration. EI and 5 NI patients were compared by using Fisher exact test or χ 2 test when appropriate for categorical 6 variables and by using Student's t test or Mann-Whitney test when appropriate for continuous 7 variables. A two-sided p value <0.05 was considered statistically significant. 8

A multivariate logistic regression model corrected by age, gender, smoking habit, available markers 9 of inflammation (CRP, PCT) and concomitant therapy with Baricitinib, a Janus kinase (JAK) 10 inhibitor, was used to quantify the odds ratios (OR) with 95% confidence interval (CI) for the 11 primary outcome occurrence on the basis of the different comorbidities. Hosmer-Lemeshow post-12 estimation test was used to assess the model performance. 13

Moreover, linear regression was used to correlate continuous variables. 14 Finally, time to event (patients' clinical improvement according to OSCI) was assessed using the 15 Kaplan-Meyer curves and compared between groups by the Long-rank test. 16

All the statistical analyses were performed using STATA 14.2 SE software (STATA Corp., College 17 Station, Texas). 18

A total of 248 COVID-19 patients were assessed for eligibility. Among them, 106 were excluded 21 because they did not meet the criteria for starting therapy with Remdesivir (n=72) or for the lack of 22 information regarding primary outcome and/or mortality (n=34). Thus, 142 patients treated with 23

The baseline anamnestic and clinical characteristics of the studied population are summarized in 1 Table 1 . One hundred and eleven patients (EI, 78.2%) showed a clinical improvement at OSCI 2 during the observational period. 3

As it was expected, EI patients were younger than NI ones (63.7 ± 13.0 vs. 74.3 ± 12.2, p<0.01). 4

The prevalence of obesity (20.7% vs. 41.9%, p=0.03), the average BMI (27.1 ± 4.4 vs. 31.1 ± 6.1, 5 p<0.01) and the mean LDL-C levels (78 ± 19 mg/dl vs. 103 ± 18 mg/dl, p=0.03) were significantly 6 lower in EI compared to NI individuals ( Table 2) . No statistically significant differences were found 7 in terms of concomitant medications at baseline for the treatment of patients' comorbidities in the 8 two studied groups ( Table 2) . 9

Among other comorbidities, obesity was negatively associated to clinical improvement after 10

Remdesivir (OR 0.48, 95%CI 0.17-0.97, p=0.04) ( Table 3) . Furthermore, both obesity (OR 2.82, 11 95% CI 1.05-7.71, p=0.04) and dyslipidemia (OR 2.78, 95%CI 1.17-7.16, p=0.03) were 12 significantly related to early patient mortality (Table 4) . 13

All the studied individuals underwent steroid therapy during hospitalization, while a similar 14 percentage of patients in the two study groups was also treated with Baricitinib: 28.8% (32/111) vs. 15 25.8% (8/31) in EI vs. NI patients, respectively (p=0.74). 16

Since Remdesivir response could be affected by the precocity of drug administration and by the 17 patients' clinical status (in terms of respiratory performance) at the time of prescription [19] , we 18 assessed these parameters in our cohort according to both dyslipidemia and obesity status. Notably, 19 the mean time for Remdesivir prescription (from the onset of symptoms) was not different in 20 dyslipidemic vs. non-dyslipidemic (4.9 ± 1.5 days vs. 4.7 ± 1.9 days, respectively, p=0.72) as well 21 as in obese vs. non-obese (5.2 ± 2.0 days vs. 4.8 ± 1.8 days, respectively, p=0.42) individuals. 22

Moreover, average PaO2/FiO2 ratio at the time of first Remdesivir administration was similar in 23 dyslipidemic vs. non-dyslipidemic (305.6 ± 107.9 vs. 321.1 ± 100.1, respectively, p=0.49) and in 24 obese vs. non-obese (315.2 ± 99.5 vs. 301.6 ± 97.5, respectively, p=0.53) patients.

A linear correlation between BMI values and the number o days needed for clinical improvement 1 was also found ( Figure 1 ). Thus, the higher was BMI in our cohort, the longer was the time needed 2 for the patient to recover. Finally, dyslipidemic subjects experienced a slower clinical improvement 3 than non-dyslipidemic ones (Long-rank p=0.04) (Figure 2 ). This clinical pattern was not evident 4 among obese patients (Long-Rank p=0.25) (Figure 3) . 5

No other statistically significant differences were found in our cohort. This study showed, for the first time to our knowledge, that unfavorable metabolic conditions such 9 as obesity and dyslipidemia could predict not only (as it is already known) the severity of clinical 10 course and mortality among SARS-CoV-2-infected individuals, but also worse clinical outcomes 11

following Remdesivir in patients who are hospitalized for moderate-to-severe disease. In our 12 population, in fact, obesity was negatively associated to clinical improvement after the antiviral 13 therapy and (together with dyslipidemia) positively related to patients' mortality. Dyslipidemia 14 affected also the rapidity of clinical response, being dyslipidemic subjects slower than non-15 dyslipidemic ones in improving their clinical condition. 16

Since COVID-19 developed and became a pandemic, it has been well established that the presence 17

of several comorbidities such as obesity and dyslipidemia represent a risk factor of clinical severity On the other hand dyslipidemia itself (which is commonly but not always related to 24 overweight/obesity) could further complicate this condition of low-level inflammatory exposure oxidized LDLs lead to several downstream consequences such as a cytokine storm [37]. Oxidized 1

cell apoptosis through the NF-kB and caspases signaling, thus increasing monocyte levels, platelet 4 activation, and vascular smooth muscle cell migration [38] . 5

Endothelial dysfunction could, indeed, have a central role in the association between 6 dyslipidemia/obesity and worse prognosis among COVID-19 patients. Since COVID-19 is widely 7 considered an endothelial disease [39, 40] and both dyslipidemia and obesity are pre-existing 8 conditions, which are known to induce endothelial dysfunction, it is likely that both of them (either 9 additionally or synergistically) may worsen the endothelial response to infection. 10

That said, it is important to underline that in our cohort the disease was identified and treated 11 precociously (less than 10 days since symptoms onset) by means of Remdesivir together with 12 standard anti-inflammatory therapy. Nevertheless, both obese and dyslipidemic individuals showed 13 significantly worse outcomes in terms of clinical improvement, time to recovery and mortality. This progression than previously thought, not only by affecting the "cytokine storm phase" (and 17 therefore determining a dysregulation of patients' immune response), but also by interfering with 18 the anti-replicative effect of an antiviral drug (e.g. Remdesivir) already from the first phases of the 19 disease (that is before the cytokine storm occurrence). Our study suggests, therefore, that treating 20 and preventing obesity and dyslipidemia during pandemic could have a central role not only by 21 decreasing inflammation-related infection severity, but also by ameliorating patients' response to 22 antivirals during the very early stages of the disease. The latter consideration appears to be 23 clinically crucial considering the importance of an early diagnosis and treatment on COVID-19-24 related outcomes. 25

This study has strengths and limitation. Among strengths both the real-world approach and the 1 novelty of the topic should be mentioned. Main limitations are represented by the retrospective 2 design of the study (whose conclusions need to be supported by further and adequately powered 3 prospective clinical studies), by the lack of a control group of Remdesivir-untreated COVID- 19 4 patients, which would have been critical to support our hypotheses, and by the lack of information 5 on several inflammation mediators (e.g. IL-6, TNF-α, etc) and on the SARS-CoV-2 viral load. 6

Another limitation regards the timing of lipid profile assessment. It is, in fact, known that 7 circulating levels of total cholesterol and LDL-C are lowered during acute infections [41, 42] . 8

Since, in our study, dyslipidemia has been defined based on either concomitant therapy with lipid-9 lowering drugs or serum LDL-C levels at hospital admission, the detected percentage of 10 dyslipidemic patients could have been underestimated. 11

Nevertheless, we believe that this paper offers useful insights regarding the impact of metabolic 12 disorders on the prognosis of COVID-19 individuals in a specific clinical setting, which is 13 represented by those hospitalized inpatients treated with Remdesivir. 14 Further larger-scale prospective studies are, however, needed to confirm our preliminary findings 15 and to identify any additional predictors of differential clinical response to Remdesivir in SARS-16

CoV-2-infected patients. 17 

Epidemiology Working Group for Ncip Epidemic Response CCfDC, Prevention. [The 2 epidemiological characteristics of an outbreak of

Factors 5 associated with hospital admission and critical illness among 5279 people with coronavirus disease 6

COVID-19 treatment options: a 8 difficult journey between failed attempts and experimental drugs

Clinical course and risk factors for mortality of 11 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prevalence and impact of diabetes among 14 people infected with SARS-CoV-2

Obesity, and Metabolic Inflammation Create the Perfect 16 Storm for COVID-19

Baseline 18 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of 19 the Lombardy Region

Association of dyslipidemia with the severity and mortality 21 of coronavirus disease 2019 (COVID-19): a meta-analysis

Baricitinib 11 plus Remdesivir for Hospitalized Adults with Covid-19

Estimation of the concentration of low-density 14 lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge

KDIGO clinical practice guidelines for acute kidney injury

Societies ESCNC. 2019 ESC/EAS guidelines for 19 the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

The Declaration of Helsinki, 50 years later

Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of 2 COVID-19: An International, Multicenter Retrospective Meta-analysis. Diabetes care

Hypertension, Diabetes and Obesity, Major Risk Factors for Death in 5 Patients with COVID-19 in Mexico

The triumvirate: why hypertension, obesity, 7 and diabetes are risk factors for adverse effects in patients with COVID-19

Risk factors associated with the 10 progression of COVID-19 in elderly diabetes patients. Diabetes research and clinical practice

Dyslipidemia 13 Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-14 regression

Indirect Effects of SARS-CoV-2 Pandemic in Subjects with Familial Hypercholesterolemia: A

Inflammatory responses and 19 inflammation-associated diseases in organs

coronavirus disease 2019: retrospective study

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19

City: a prospective cohort study. medRxiv : the preprint server for health sciences

Obesity and inflammation: the linking 6 mechanism and the complications. Archives of medical science

Impact of Obesity and Metabolic Syndrome on

Altered respiratory physiology in obesity. Canadian 12 respiratory journal

Obesity reviews : an official journal of 14 the International Association for the Study of Obesity

Association 16 of Obesity with Disease Severity Among Patients with Coronavirus Disease

Physiological and Immunological Causes of the Susceptibility of

Chronic Inflammatory Patients to COVID-19 Infection: Focus on Diabetes. Frontiers in 20 endocrinology

Induction of MIF expression by

Low Brachial

Artery Flow-Mediated Dilation Predicts Worse Prognosis in Hospitalized Patients with COVID-19

COVID-19 is, in the end, an endothelial disease

Effects 6 of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences 7 to the host

Changes in serum 9 lipoprotein pattern induced by acute infections